AI Article Synopsis
- The study aimed to compare the levels of certain blood markers (PAI-1, CRP, SAA, and IL-6) in patients with ST elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction (NSTEMI).
- Seventy-six patients (37 with STEMI and 39 with NSTEMI) provided blood samples within 6 hours of presenting with acute myocardial infarction to measure these markers.
- Results indicated that PAI-1 levels were significantly higher in STEMI patients compared to NSTEMI patients, while the other markers showed no significant difference, suggesting that elevated PAI-1 may play a role in the higher incidence of occlusive thrombi in STEMI cases.
Article Abstract
Objectives: Myocardial infarction (MI) may be classified as ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI). Procoagulants such as plasminogen activator inhibitor-1 (PAI-1) as well as markers of inflammation such as C-reactive protein (CRP), serum amyloid A (SAA) and interleukin-6 (IL-6) are elevated in acute coronary syndromes. However, no study has examined whether levels of these markers differ in patients with STEMI as opposed to NSTEMI. We sought to determine whether there are differences in plasma levels of PAI-1, CRP, SAA or IL-6 in patients with STEMI compared to patients with NSTEMI.
Methods: Seventy-six consecutive patients presenting with acute MI (37 with STEMI and 39 with NSTEMI) were prospectively enrolled. Blood samples were obtained from patients within 6 h from presentation and plasma PAI-1, CRP, IL-6 and SAA concentrations were measured.
Results: Plasma levels of PAI-1 were significantly higher in patients with STEMI compared to NSTEMI: 85.7 +/- 5 vs. 61.3 +/- 5 ng/ml (p < 0.001), while CRP, SAA and IL-6 levels were not significantly different between STEMI and NSTEMI patients.
Conclusions: Higher plasma PAI-1 levels in STEMI patients may contribute to the predilection of these patients to occlusive thrombi and STEMI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000137700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-risk electrocardiogram presentations in the acute coronary syndrome patient - Beyond ST-segment elevation myocardial infarction.
Turk J Emerg Med
January 2025
Department of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
This review considers high-risk electrocardiographic patterns in the acute coronary syndrome (ACS) patient; we review 7 electrocardiogram presentations lacking diagnostic criteria for ST-segment elevation myocardial infarction (STEMI) yet likely representing either STEMI equivalent syndromes or ACS presentations with significant short-and long-term risk. The STEMI equivalent presentations include acute posterior wall myocardial infarction, the hyperacute T-wave of early STEMI, de Winter syndrome, first diagonal of the left anterior descending artery occlusion, and left bundle branch block modified Sgarbossa positive findings. High-risk presentation, not felt to be STEMI equivalent entities yet still possessing significant risk of short-and long-term adverse outcome, include lead aVR ST-segment elevation and Wellens syndrome.
View Article and Find Full Text PDFImpact of pulmonary artery catheterization in patients with acute myocardial infarction cardiogenic shock.
Cardiovasc Revasc Med
January 2025
Department of Cardiology, MedStar Georgetown University Hospital/MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Acute myocardial infarction (AMI) remains one of the most common causes for cardiogenic shock (CS), with high inpatient mortality (40-50 %). Studies have reported the use of pulmonary artery catheters (PACs) in decompensated heart failure, but contemporary data on their use to guide management of AMI-CS and in different SCAI stages of CS are lacking. We investigated the association of PACs and clinical outcomes in AMI-CS.
View Article and Find Full Text PDFTongxinluo capsules for secondary prevention after ST-segment elevation myocardial infarction: A systematic review and meta-analysis.
J Ethnopharmacol
January 2025
Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address:
Ethnopharmacological Relevance: Tongxinluo (TXL), a Chinese patent medicine, is commonly used for secondary prevention of cardiovascular events.
Aim Of The Study: To evaluate the efficacy and safety of TXL for secondary prevention after ST-segment elevation myocardial infarction (STEMI).
Materials And Methods: A search for relevant randomized controlled trials (RCTs) was conducted across seven electronic databases from inception to May 10, 2024.
The monocyte-to-HDL-cholesterol ratio predicts new-onset atrial fibrillation in patients with acute STEMI.
Biomark Med
January 2025
Department of Cardiology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
Objective: Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.
Methods: Between July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed.
Optimal timing of pharmacoinvasive strategy and its impact on clinical and economic outcomes in patients with ST-elevation myocardial infarction: a real-world perspective.
Front Cardiovasc Med
January 2025
Laboratory of Data for Quality of Care and Outcomes Research (LaDa:QCOR), Catholic University of Brasilia, Brasília, Brazil.
Background: The pharmacoinvasive (PhI) strategy is the standard-of-care for ST-elevation myocardial infarction (STEMI) patients when primary percutaneous coronary intervention (pPCI) is unfeasible. Optimal timing for post-fibrinolytic PCI (lysis-PCI) remains elusive. Therefore, this study aimed to assess the clinical and economic impacts of early vs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!